Second Launch For Rozlytrek, In Japan, But Sales Prospects Limited
Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.
Chugai says coronavirus business impact has been minor so far but cautions this could change after a strong first quarter.